As the therapeutic picture for hepatitis C begins to settle down, the volume of abstracts on the topic is plateauing at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).

That’s not to say that new HCV therapies won’t get a lot of play, according to Gary Davis, MD, president of MedLogician Consulting of Ponte Vedra Beach, Fla., and secretary of the liver association.

But, he told MedPage Today in advance of the meeting, “there’s a big shift toward fatty liver disease … that reflects what people are seeing in the clinics.”

Continue Reading

READ FULL ARTICLE Curated publisher From Medical Page Today